Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $90000.0.

  • Day One Biopharmaceuticals' Depreciation & Amortization (CF) rose 46250.0% to $90000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $313000.0, marking a year-over-year increase of 36716.42%. This contributed to the annual value of $92000.0 for FY2024, which is 15555.56% up from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Depreciation & Amortization (CF) is $90000.0, which was up 46250.0% from $91000.0 recorded in Q2 2025.
  • Day One Biopharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $94000.0 during Q1 2025, with a 5-year trough of $6000.0 in Q1 2022.
  • Over the past 4 years, Day One Biopharmaceuticals' median Depreciation & Amortization (CF) value was $15000.0 (recorded in 2022), while the average stood at $31066.7.
  • Per our database at Business Quant, Day One Biopharmaceuticals' Depreciation & Amortization (CF) plummeted by 6944.44% in 2023 and then surged by 50666.67% in 2025.
  • Day One Biopharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $15000.0 in 2022, then dropped by 13.33% to $13000.0 in 2023, then surged by 192.31% to $38000.0 in 2024, then soared by 136.84% to $90000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $90000.0 for Q3 2025, versus $91000.0 for Q2 2025 and $94000.0 for Q1 2025.